Massively parallel de novo protein design for targeted therapeutics

Nature

Volumn 550, Issue 7674, 2017, Pages 74-79

  Chevalier, Aaron ^a,b   Silva, Daniel Adriano ^a,b   Rocklin, Gabriel J ^a,b   Hicks, Derrick R ^a,b   Vergara, Renan ^a,b,c   Murapa, Patience ^b   Bernard, Steffen M ^d   Zhang, Lu ^e,f   Lam, Kwok Ho ^g   Yao, Guorui ^g   Bahl, Christopher D ^a,b   Miyashita, Shin Ichiro ^f,h   Goreshnik, Inna ^a   Fuller, James T ^b   Koday, Merika T ^b,i   Jenkins, Cody M ^b   Colvin, Tom ^a   Carter, Lauren ^b   Bohn, Alan ^b   Bryan, Cassie M ^d   Fernández Velasco, D Alejandro ^a,b   Stewart, Lance ^c   Dong, Min ^b   Huang, Xuhui ^f,h   Jin, Rongsheng ^f   Wilson, Ian A ⁱ   Fuller, Deborah H ^d   Baker, David ^a,b   more..

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER   (China)

^f HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ Virvio Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; BOTULINUM TOXIN B; INFLUENZA VIRUS HEMAGGLUTININ; OLIGONUCLEOTIDE; BOTULINUM TOXIN; PROTEIN; PROTEIN BINDING;

ANTIBODY; GENETIC ANALYSIS; HIGH TEMPERATURE; IMMUNE RESPONSE; INFLUENZA; PROTEIN; YEAST;

ARTICLE; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; IMMUNE RESPONSE; MATHEMATICAL MODEL; NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; CHEMISTRY; CLASSIFICATION; COMPUTER SIMULATION; HEAT; HUMAN; IMMUNOLOGY; INFLUENZA; METABOLISM; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; PROCEDURES; PROTEIN ENGINEERING; PROTEIN STABILITY; TEMPERATURE;

BOTULINUM TOXINS; COMPUTER SIMULATION; DRUG DESIGN; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HOT TEMPERATURE; HUMANS; INFLUENZA, HUMAN; MOLECULAR DYNAMICS SIMULATION; MOLECULAR TARGETED THERAPY; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN STABILITY; PROTEINS; TEMPERATURE;

EID: 85030668169     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature23912     Document Type: Article

References (48)

1. Kintzing, J. R., Cochran, J. R. Engineered knottin peptides as diagnostics, therapeutics, and drug delivery vehicles. Curr. Opin. Chem. Biol. 34, 143-150 (2016).
2. Gebauer, M., Skerra, A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr. Opin. Chem. Biol. 13, 245-255 (2009).
3. Zahnd, C., et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: Effects of affinity and molecular size. Cancer Res. 70, 1595-1605 (2010).
4. Vazquez-Lombardi, R., et al. Challenges and opportunities for non-antibody scaffold drugs. Drug Discov. Today 20, 1271-1283 (2015).
5. Bhardwaj, G., et al. Accurate de novo design of hyperstable constrained peptides. Nature 538, 329-335 (2016).
6. Rocklin, G. J., et al. Global analysis of protein folding using massively parallel design, synthesis, and testing. Science 357, 168-175 (2017).
7. Berger, S., et al. Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer. eLife 5, e20352 (2016).
8. Procko, E., et al. A computationally designed inhibitor of an Epstein-Barr viral Bcl-2 protein induces apoptosis in infected cells. Cell 157, 1644-1656 (2014).
9. Cleary, M. A., et al. Production of complex nucleic acid libraries using highly parallel in situ oligonucleotide synthesis. Nat. Methods 1, 241-248 (2004).
10. Sun, M. G. F., Seo, M.-H., Nim, S., Corbi-Verge, C., Kim, P. M. Protein engineering by highly parallel screening of computationally designed variants. Sci. Adv. 2, e1600692 (2016).
11. Fleishman, S. J., et al. RosettaScripts: A scripting language interface to the Rosetta macromolecular modeling suite. PLoS One 6, e20161 (2011).
12. Hurt, A. C., et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: Public health, laboratory, and clinical perspectives. Lancet Infect. Dis. 12, 240-248 (2012).
13. Blitzer, A. Spasmodic dysphonia and botulinum toxin: Experience from the largest treatment series. Eur. J. Neurol. 17, (Suppl 1), 28-30 (2010).
14. Koday, M. T., et al. A computationally designed hemagglutinin stem-binding protein provides in vivo protection from influenza independent of a host immune response. PLoS Pathog. 12, e1005409 (2016).
15. Whitehead, T. A., et al. Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing. Nat. Biotechnol. 30, 543-548 (2012).
16. Fleishman, S. J., et al. Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science 332, 816-821 (2011).
17. Berntsson, R. P. A., Peng, L., Dong, M., Stenmark, P. Structure of Botulinum neurotoxin B binding domain in complex with both synaptotagmin II and GD1a. RCSB Protein Data Bank. http://dx.doi.org/10.2210/pdb4kbb/pdb. (2013).
18. Corti, D., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856 (2011).
19. Cass, L. M. R., Efthymiopoulos, C., Bye, A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin. Pharmacokinet. 36 (Suppl. 1), 1-11 (1999).
20. King, C., et al. Removing T-cell epitopes with computational protein design. Proc. Natl Acad. Sci. USA 111, 8577-8582 (2014).
21. Huang, P.-S., et al. RosettaRemodel: A generalized framework for flexible backbone protein design. PLoS One 6, e24109 (2011).
22. Lin, Y.-R., et al. Control over overall shape and size in de novo designed proteins. Proc. Natl Acad. Sci. USA 112, E5478-E5485 (2015).
23. Koga, N., et al. Principles for designing ideal protein structures. Nature 491, 222-227 (2012).
24. Silva, D.-A., Correia, B. E., Procko, E. Motif-driven design of protein-protein interfaces. Methods Mol. Biol. 1414, 285-304 (2016).
25. Hoover, D. M., Lubkowski, J. DNAWorks: An automated method for designing oligonucleotides for PCR-based gene synthesis. Nucleic Acids Res. 30, e43 (2002).
26. Bawono, P., Heringa, J. PRALINE: A versatile multiple sequence alignment toolkit. Methods in Mol. Biol. 1079, 245-262 (2013).
27. Zhang, J., Kobert, K., Flouri, T., Stamatakis, A. PEAR: A fast and accurate Illumina Paired-End reAd mergeR. Bioinformatics 30, 614-620 (2014).
28. Waskom, M., et al. seaborn: V0.7.1. http://dx.doi.org/:10.5281/zenodo.54844 (2016).
29. Chao, G., et al. Isolating and engineering human antibodies using yeast surface display. Nat. Protocols 1, 755-768 (2006).
30. Benatuil, L., Perez, J. M., Belk, J., Hsieh, C.-M. An improved yeast transformation method for the generation of very large human antibody libraries. Protein Eng. Des. Sel. 23, 155-159 (2010).
31. Jacobs, T. M., Yumerefendi, H., Kuhlman, B., Leaver-Fay, A. SwiftLib: Rapid degenerate-codon-library optimization through dynamic programming. Nucleic Acids Res. 43, e34 (2015).
32. Jin, R., Rummel, A., Binz, T., Brunger, A. T. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444, 1092-1095 (2006).
33. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
34. Emsley, P., Cowtan, K. Coot: Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
35. McCoy, A. J., et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
36. Brünger, A. T. Free R value: A novel statistical quantity for assessing the accuracy of crystal structures. Nature 355, 472-475 (1992).
37. Chen, V. B., et al. MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21 (2010).
38. Otwinowski, Z., Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
39. Adams, P. D., et al. The Phenix software for automated determination of macromolecular structures. Methods 55, 94-106 (2011).
40. Gamblin, S. J., et al. The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 303, 1838-1842 (2004).
41. Van Der Spoel, D., et al. GROMACS: Fast, flexible, and free. J. Comput. Chem. 26, 1701-1718 (2005).
42. Lindorff-Larsen, K., et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 78, 1950-1958 (2010).
43. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926-935 (1983).
44. Hess, B., Bekker, H., Berendsen, H. J. C., Fraaije, J. G. E. M. LINCS: A linear constraint solver for molecular simulations. J. Comput. Chem. 18, 1463-1472 (1997).
45. Essmann, U., et al. A smooth particle mesh Ewald method. J. Chem. Phys. 103, 8577-8593 (1995).
46. Berendsen, H. J. C. in Computer Simulation in Materials Science (eds Meyer. M., Pontikis, V.) 139-155 (Springer, 1991).
47. Bussi, G., Donadio, D., Parrinello, M. Canonical sampling through velocity rescaling. J. Chem. Phys. 126, 014101 (2007).
48. Nosé, S., Klein, M. L. Constant pressure molecular dynamics for molecular systems. Mol. Phys. 50, 1055-1076 (1983).